Cargando…

Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry

Few studies have reported the association between body mass index (BMI) and outcome among Asian breast cancer patients. We analyzed data for 20,090 female invasive breast cancer patients who had been followed‐up for a median period of 6.7 years entered in the National Clinical Database–Breast Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawai, Masaaki, Tomotaki, Ai, Miyata, Hiroaki, Iwamoto, Takayuki, Niikura, Naoki, Anan, Keisei, Hayashi, Naoki, Aogi, Kenjiro, Ishida, Takanori, Masuoka, Hideji, Iijima, Kotaro, Masuda, Shinobu, Tsugawa, Koichiro, Kinoshita, Takayuki, Nakamura, Seigo, Tokuda, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924391/ https://www.ncbi.nlm.nih.gov/pubmed/26923549 http://dx.doi.org/10.1002/cam4.678

Ejemplares similares

Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry
por: Iwamoto, Takayuki, et al.
Publicado: (2016)

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry
por: Kataoka, Akemi, et al.
Publicado: (2016)

Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006
por: Iwamoto, Takayuki, et al.
Publicado: (2015)

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004
por: Kinoshita, Takayuki, et al.
Publicado: (2015)

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005
por: Anan, Keisei, et al.
Publicado: (2015)

A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study
por: Kubo, Makoto, et al.
Publicado: (2019)

Annual report of the Japanese Breast Cancer Society registry for 2016
por: Kubo, Makoto, et al.
Publicado: (2020)

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2022)

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
por: Takano, Toshimi, et al.
Publicado: (2023)

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
por: Hayashi, Naoki, et al.
Publicado: (2017)

Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study
por: Toi, Masakazu, et al.
Publicado: (2013)

Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018
por: Tada, Keiichiro, et al.
Publicado: (2022)

Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
por: Ogiya, Rin, et al.
Publicado: (2016)

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers
por: Iwamoto, Takayuki, et al.
Publicado: (2017)

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer
por: Aogi, Kenjiro, et al.
Publicado: (2015)

Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study
por: Kadoya, Takayuki, et al.
Publicado: (2013)

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
por: Iwamoto, Takayuki, et al.
Publicado: (2019)

Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment
por: Hanamura, Toru, et al.
Publicado: (2023)

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
por: Masuyama, Misato, et al.
Publicado: (2023)

Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression
por: Hanamura, Toru, et al.
Publicado: (2022)

Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment
por: Hanamura, Toru, et al.
Publicado: (2023)

Chemotherapy resumption in breast cancer patient after COVID-19
por: Horiguchi, Julian, et al.
Publicado: (2021)

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
por: Kawaguchi, Hidetoshi, et al.
Publicado: (2019)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Density of breast: An independent risk factor for developing breast cancer, a prospective study at two premium breast centers
por: Lo, Chia Hwee, et al.
Publicado: (2020)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
por: Shien, Tadahiko, et al.
Publicado: (2014)

Breast cancer supplemental screening: Women’s knowledge and utilization in the era of dense breast legislation
por: Aminawung, Jenerius A., et al.
Publicado: (2020)

Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan
por: Ishii, Taisuke, et al.
Publicado: (2020)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Impact of reproductive factors on breast cancer incidence: Pooled analysis of nine cohort studies in Japan
por: Takeuchi, Taro, et al.
Publicado: (2021)

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
por: Posso, Margarita, et al.
Publicado: (2017)

Association between breast cancer and thyroid cancer: A study based on 13 978 patients with breast cancer
por: Huang, Nai‐si, et al.
Publicado: (2018)

Outcomes and risk of subsequent breast events in breast‐conserving surgery patients with BRCA1 and BRCA2 mutation
por: Ye, Fugui, et al.
Publicado: (2020)

Adenocarcinoma of the Breast Presenting as Occult Breast Cancer With Axillary and Supraclavicular Lymph Node Metastasis: A Case Report
por: Aleman Espino, Andy, et al.
Publicado: (2023)

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011)

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
por: Ueno, Takayuki, et al.
Publicado: (2022)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

Breast cancer screening: Impact on care pathways
por: Lefeuvre, Delphine, et al.
Publicado: (2019)

Ductal carcinoma in situ arising in tubular adenoma of the breast
por: Saimura, Michiyo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6kuvacgg07375o23t4no9a55mm